Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Study Design Overview Patient Timeline: * Patients will start first-line therapy with ADC (not yet enrolled on this study) * Patients provide tumor tissue (frozen in AllProtect) to BreakBio for analysis in the first 10 weeks of ADC therapy (patients sign 1st consent to share tumor tissue with BreakBio). Biopsy can be from primary site or metastatic site. BreakBio will provide detailed reports from DNA and RNA analysis to treating physician (not yet enrolled on this study) * Patients who progress on first-line ADC therapy are pre-screened for this study (not yet enrolled on this study) * Patients who pass the pre-screening for this study start 2 cycles of induction chemotherapy of physician's choice. Treating physician informs BreakBio to begin manufacturing BreakVax (not yet enrolled on this study) * After 2 cycles of induction chemotherapy, patients are screened for eligibility for this study. If BreakVax manufacturing is delayed, patients should complete a 3rd cycle of induction chemotherapy before screening. Patients are only eligible if they do not experience progression during these induction chemotherapy cycles (not yet enrolled on this study) * Patients who pass screening will sign 2nd consent to enroll in study (enrolled in study) * The first 3 patients, who are enrolled on Substudy A or B or a combination of both, will comprise the Safety Lead-in Cohort (no randomization, as detailed below) (enrolled in study) * After the Safety Lead-in Cohort is complete, further patients will be randomized to either the BreakVax Arm or the Delayed BreakVax Arm as detailed below (enrolled in study) Safety Lead-in Cohort The first three patients, who are enrolled on Substudy A or B or a combination of both, will comprise a Safety Lead-in Cohort to characterize dose-limiting toxicities (DLTs) and early safety. For Substudy A, the treatment cycle is 21 days, however, the DLT evaluation period will be 28 days. These patients will receive 2 cycles of induction chemotherapy (Cycles -1 and -2), followed by a 28 day DLT evaluation period (21 days of Cycle 1 and 7 days of Cycle 2). * Treatment: In the first 21 days (Cycle 1) formulated BreakVax and low-dose subcutaneous ipilimumab (administered locally at the injection site as a local dendritic cell adjuvant to enhance T-cell priming) will be administered without chemotherapy or other combination drugs. Then, patients will proceed to Cycle 2 of the BreakVax Arm, where they will receive BreakVax and all combination drugs. * Monitoring: Patients will be monitored over 28 days (21 days with BreakVax and low-dose ipilimumab alone, and then the first 7 days of Cycle 2 of the BreakVax Arm, where they will receive BreakVax and all combination drugs) for DLTs. * Following completion of the DLT evaluation period (28-days), patients will continue with Cycle 2 of the BreakVax Arm. After the three patients in the Safety Lead-in Cohort have completed the DLT evaluation period (either as part of Substudy A or B or a combination of both), the randomized phase of the study will begin. If ≥2 DLTs are observed among the initial 3 patients, an additional 3 patients, who will be enrolled on Substudy A or B or a combination of both, will be enrolled in the Safety Lead-in Cohort. If ≥3 DLTs are observed among the 6 patients, continuation of the study will be reviewed by the Safety Monitoring Committee (SMC), which may recommend study termination based on safety findings. Randomized Combination Therapy Cohort Following completion of the Safety Lead-in Cohort, 10 patients will be randomized in a 1:1 ratio to one of the following arms: * BreakVax Arm: BreakVax formulated with adjuvants and low-dose subcutaneous ipilimumab (as a local dendritic cell adjuvant) in combination with pembrolizumab, losartan, aspirin, and SOC chemotherapy of physician's choice. * Delayed BreakVax Arm: SOC chemotherapy of physician's choice until disease progression per iRECIST. Upon progression, patients will cross over to receive the study combination regimen, including BreakVax formulated with adjuvants, low-dose subcutaneous ipilimumab (as a local dendritic cell adjuvant), pembrolizumab, losartan, aspirin, and chemotherapy of physician's choice. Treatment Schedule: A treatment cycle is defined as 21 days. BreakVax Arm BreakVax, in combination with its adjuvants and low-dose subcutaneous ipilimumab (as a local dendritic cell adjuvant) will be administered on Day 1 of Cycles 1, 2, and 3. Thereafter, BreakVax will be administered on Day 1 of every even cycle (i.e. cycles 4, 6, 8, etc.) until disease progression per iRECIST or other discontinuation criteria. In addition to BreakVax: * Losartan will be administered orally once daily throughout treatment. * Chemotherapy of physician's choice will be administered per the selected regimen within each 21-day cycle. Steroid-containing premedications are not permitted (see Disallowed Concomitant Medications listed below). * Aspirin will be administered orally once daily, except on Days 1, 2, and 3 of cycles in which BreakVax is administered. * Pembrolizumab will be initiated on Day 10 of Cycle 4 and will thereafter be administered on Day 10 of every even-numbered cycle (i.e., Cycles 4, 6, 8, etc.) until disease progression or discontinuation. Delayed BreakVax Arm Patients randomized to the Delayed BreakVax Arm will receive chemotherapy of physician's choice in each 21-day cycle until disease progression per iRECIST. Upon documented disease progression, patients will cross over to receive the full combination regimen, including BreakVax with adjuvants, low-dose subcutaneous ipilimumab (as a local dendritic cell adjuvant), pembrolizumab, losartan, aspirin, and chemotherapy of physician's choice, according to the BreakVax Arm schedule.